Liposomal amphotericin B related late-onset hyperphosphatemia in a pediatric patient with acute myeloid leukemia

Abstract

Introduction

Children with acute myeloid leukemia (AML) are at risk for serious electrolyte abnormalities.

Case report

We reported a case of hyperphosphatemia in a child with acute myeloid leukemia who received liposomal amphotericin B (AMBL) for the treatment of an invasive fungal infection. The findings of this case suggest that cumulative dose accumulation due to long term AMBL treatment may result in late-onset hyperphosphatemia.

Management and outcome

This is the first case report in the literature that of late-onset hyperphosphatemia (day 56) in a patient with low-dose AMBL treatment (3–5 mg/kg/day) and normal renal function.

Discussion

We highlight the importance of increasing awareness of AMBL related hyperphosphatemia among healthcare providers.